Clinical proteomics and OMICS clues useful in translational medicine research

López, Elena; Madero, Luís; López-Pascual, J.; Latterich, Martin

doi:10.1186/1477-5956-10-35

“…Much of the current, aggressive search for biomarkers in cancer and other disease has focused largely on a proteomic approach to identify these distinctive molecular signatures, but this approach has met with varying success [25], [26]. In the current investigation, we have chosen to utilize the somewhat less commonly applied, but effective [24], [27]–[33], transcriptomics-first approach to inform the proteomics.…”

Section: Discussionmentioning

confidence: 99%

Prospective Transcriptomic Pathway Analysis of Human Lymphatic Vascular Insufficiency: Identification and Validation of a Circulating Biomarker Panel

Lin

¹

,

Kim

²

,

Lee

³

et al. 2012

View full text Add to dashboard Cite

BackgroundIn our previous transcriptional profiling of a murine model, we have identified a remarkably small number of specific pathways with altered expression in lymphedema. In this investigation, we utilized microarray-based transcriptomics of human skin for an unbiased a priori prospective candidate identification, with subsequent validation of these candidates through direct serum assay. The resulting multi-analyte biomarker panel sensitively should sensitively discriminate human lymphedema subjects from normal individuals.Methods and FindingsWe enrolled 63 lymphedema subjects and 27 normals in our attempt to discover protein analytes that can distinguish diseased individuals from controls. To minimize technical and biologically irrelevant variation, we first identified potential candidates by performing transcriptional microarray analysis on paired diseased and normal skin specimens sampled from the same individuals. We focused our attention on genes with corresponding protein products that are secreted and took these candidates forward to a protein multiplex assay applied to diseased and normal subjects. We developed a logistic regression-based model on an eventual group of six proteins and validated our system on a separate cohort of study subjects. The area under the receiver operating characteristic curve was calculated to be 0.87 (95% CI : 0.75 to 0.97).ConclusionsWe have developed an accurate bioassay utilizing proteins representing four central pathogenetic modalities of the disease: lymphangiogenesis, inflammation, fibrosis, and lipid metabolism, suggesting that these proteins are directly related to the pathogenesis of the tissue pathology in lymphatic vascular insufficiency. Further studies are warranted to determine whether this newly-identified biomarker panel will possess utility as an instrument for in vitro diagnosis of early and latent disease; the ultimate applicability to risk stratification, quantitation of disease burden, and response to therapy can easily be envisioned.

show abstract

“…The field of clinical proteomics has aroused great interest in the search for protein or peptidic biomarkers, since mass spectrometry has been able to characterize a large number of proteins and their post-translational modifications under different biological conditions. [ 21 – 23 ].…”

Section: Discussionmentioning

confidence: 99%

Ceruloplasmin, transferrin and apolipoprotein A-II play important role in treatment's follow-up of paracoccidioidomycosis patients

Sylvestre

¹

,

Cavalcante

²

,

Silva

³

et al. 2018

View full text Add to dashboard Cite

Paracoccidioidomycosis (PCM) is a systemic disease caused by thermodymorphic fungi of the Paracoccidioides brasiliensis complex, (Paracoccidioides spp.). Patients with PCM reveal specific cellular immune impairment. Despite the effective treatment, quiescent fungi can lead to relapse, usually late, the serological diagnosis of which has been deficient. The present study was carried out with the objective of investigating a biomarker for the identification of PCM relapse and another molecule behaving as an immunological recovery biomarker; therefore, it may be used as a cure criterion. In the evolutionary analysis of the proteins identified in PCM patients, comparing those that presented with those that did not reveal relapse, 29 proteins were identified. The interactions observed between the proteins, using transferrin and haptoglobin, as the main binding protein, were strong with all the others. Patient follow-up suggests that cerulosplamin may be a marker of relapse and that transferrin and apolipoprotein A-II may contribute to the evaluation of the treatment efficacy and avoiding a premature decision.

show abstract

“…The field of clinical proteomics has aroused great interest in the search for protein or peptidic biomarkers, since mass spectrometry has been able to characterize a large number of proteins and their post-translational modifications under different biological conditions. [21][22][23].…”

Section: Discussionmentioning

confidence: 99%

Ceruloplasmin, transferrin and apolipoprotein A-IIplay important hole in treatment’s follow-up of paracoccidioidomycosis patients.

Mendes¹

2018

Preprint

0

View full text Add to dashboard Cite

Paracoccidioidomycosis (PCM) is a systemic disease caused by thermodymorphic fungi of the Paracoccidioides brasiliensis complex, (Paracoccidioides spp.). Patients with PCM reveal specific cellular immune impairment. Despite the effective treatment, quiescent fungi can lead to relapse, usually late, the serological diagnosis of which has been deficient. The present study was carried out with the objective of investigating a biomarker for the identification of PCM relapse and another molecule behaving as an immunological recovery biomarker; therefore, it may be used as a cure criterion. In the evolutionary analysis of the proteins identified in PCM patients, comparing those that presented with those that did not reveal relapse, 29 proteins were identified. The interactions observed between the proteins, using transferrin and haptoglobin, as the main binding protein, were strong with all the others. Patient follow-up suggests that cerulosplamin may be a marker of relapse and that transferrin and apolipoprotein A-II may contribute to the evaluation of the treatment efficacy and avoiding a premature decision.

show abstract

Clinical proteomics and OMICS clues useful in translational medicine research

Cited by 27 publications

References 70 publications

Prospective Transcriptomic Pathway Analysis of Human Lymphatic Vascular Insufficiency: Identification and Validation of a Circulating Biomarker Panel

Prospective Transcriptomic Pathway Analysis of Human Lymphatic Vascular Insufficiency: Identification and Validation of a Circulating Biomarker Panel

Ceruloplasmin, transferrin and apolipoprotein A-II play important role in treatment's follow-up of paracoccidioidomycosis patients

Ceruloplasmin, transferrin and apolipoprotein A-IIplay important hole in treatment’s follow-up of paracoccidioidomycosis patients.

Contact Info

Product

Resources

About